This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.

Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance

The arrhythmia events of 14-day continuous ECG patch monitor (investigational device) and 24-hour Holter monitor will be analyzed by the qualified ECG technicians and determined by physician investigators at the study sites. Arrhythmia events are defined as detection of any 1 of 6 arrhythmias, including:

• Supraventricular tachycardia (>4 beats, not including atrial fibrillation or flutter)
• Atrial fibrillation/flutter (>4 beats)
• Pause >3 seconds
• Atrioventricular block (Second-degree, 2:1 or third-degree atrioventricular block, need an advanced determination by the investigators)
• Ventricular tachycardia (>4 beats)
• Polymorphic ventricular tachycardia/ventricular fibrillation In the end, all the detection will be confirmed by the investigators.

McNemar's tests will be used to compare the matched pairs of proportion data.

The wearing time will be recorded as the day of 14-day continuous ECG patch removal after stating monitoring. Kaplan-Meier method will be reported for total wearing time. The mean value along with two-sided 95% confidence intervals will be report as well.